No. You should not use a TENS unit if you have a pacemaker or an implantable cardioverter-defibrillator (ICD), because the electrical current can interfere with the device. Standard labeling for TENS devices lists implanted electronic devices, including pacemakers, as a contraindication. The only safe path is explicit clearance from the cardiology team that manages the device, based on its specific model and programming.
How TENS current reaches a pacemaker
TENS delivers pulsed electrical current across the skin through two or more surface electrodes. The current is small, typically in the range of a few milliamps to roughly 100 mA peak depending on the device and setting, but it is deliberately designed to penetrate tissue deeply enough to depolarize sensory nerve fibers.
That same current does not stay confined to the skin. It spreads through the body's conductive tissues and creates an electric field. A pacemaker or ICD senses cardiac electrical activity through leads that touch the heart muscle, and those leads are exquisitely sensitive amplifiers. They are built to detect signals in the range of millivolts, so a field of even a few volts per meter at the lead can exceed the sensing threshold.
The interference happens through two routes. The first is direct electromagnetic coupling: TENS current induces voltage on the lead conductor, which the device may misinterpret. The second is current traveling through the body to the device's housing or leads, which is more likely when electrodes sit close to the generator or along the lead path. Pacing circuits can be inhibited, triggered inappropriately, or in the case of ICDs, misinterpreted as a dangerous rhythm.
An ICD carries the higher-stakes risk. If interference is read as ventricular fibrillation, the device can deliver a shock that the patient did not need. That is why the concern is not theoretical discomfort but an inappropriate therapy with real harm potential.
What the numbers show
The research base here is thinner than for many device interactions, and much of it is older. Testing has generally found that TENS applied to the chest wall or upper back near a device produces the highest interference risk, while applications to the lower back or limbs are farther from the sensing circuit. Distance matters: signal strength falls with the square of distance from the electrode, so an electrode 2 cm from the generator is a very different exposure than one on the calf.
Device behavior depends on the sensing configuration. Bipolar sensing, where the device measures voltage between two closely spaced lead electrodes, is more resistant to far-field interference than unipolar sensing, which references the generator can and picks up broader fields. Many modern pacemakers default to bipolar sensing, but ICDs and some pacing configurations still use unipolar settings, and these change the risk profile.
TENS frequency also matters. Most units operate between roughly 1 Hz and 150 Hz, and the pulsed output at these rates can fall within or near the band a device uses to identify intrinsic cardiac signals. Continuous output creates more opportunity for a sensed event than burst modes.
There is no validated "safe distance" number that applies across devices. Professional guidance, including cardiac device consensus statements, generally advises avoiding TENS over or near an implanted device and deferring to the managing cardiology team for any use elsewhere. [FDA device labeling and manufacturer manuals state the contraindication directly; check the specific TENS unit's instructions for use.]
Edge cases that change the risk
Site of application is the largest modifier. Electrodes placed on the upper chest, shoulder, or upper back sit close to the generator pocket and the lead path, and this is the configuration most associated with interference. Lower back, hip, knee, and foot placements are farther away but not automatically safe, because current still flows through the torso.
Device type matters. A pacemaker dependent on pacing to maintain a normal heart rate faces a different consequence from interference than a device that only paces occasionally. An ICD has the shock risk. Cardiac resynchronization devices combine pacing and defibrillation functions.
The patient's own rhythm is a factor. A person with complete heart block who relies entirely on the pacemaker has no intrinsic backup if pacing is inhibited, so even brief interference is more consequential. Someone with a strong underlying rhythm has more margin.
Device age and programming are variables a patient usually cannot assess. Modern devices have filters and noise-rejection algorithms designed to reject non-cardiac signals, and these differ by manufacturer and generation. Only the device clinic can say what protections are active.
A counterintuitive detail: the risk is not only inhibition. Interference can also cause oversensing that triggers pacing at inappropriate rates, or in rate-responsive pacemakers, alter the sensor-driven rate. The failure mode is bidirectional, which is one reason blanket reassurance is impossible.
Misconceptions worth correcting
The most common misconception is that low-output TENS is too weak to matter. In fact, the device's sensing circuit is designed to detect millivolt-level signals, so "weak" is a category error; what matters is whether the induced voltage crosses the sensing threshold at the lead.
Another is that the generator is the only vulnerable part. The leads are the antenna, and they run from the pocket through the veins into the heart. Interference couples to the lead, not just the can.
A third is that past TENS use without symptoms proves safety. Interference can be intermittent and setting-dependent, and an asymptomatic session does not rule out inhibited pacing or a near-threshold sensed event. Absence of symptoms is not evidence of absence of effect.
Finally, many people assume the device clinic can simply "shield" the pacemaker. There is no patient-level shielding solution that makes TENS reliably safe; the practical answer is avoidance or a supervised trial, not a protective accessory.
Practical steps and thresholds
Do not self-clear. The decision belongs to the cardiology or device clinic team that follows the pacemaker or ICD, because they know the model, lead configuration, sensing mode, and the patient's pacing dependency.
Ask the device clinic these specific questions: Is the device programmed to bipolar sensing? Is the patient pacing-dependent? What is the documented underlying rhythm? Is there any prior recorded episode of electromagnetic interference? What distance and electrode placement, if any, would the clinic consider acceptable?
If clearance is given, the clinic may specify a limited trial with these guardrails:
Keep electrodes at least 6 inches (about 15 cm) away from the generator pocket and lead path, and never on the chest, shoulder, or upper back. Use the lowest effective amplitude and the shortest session, then stop and report any palpitations, dizziness, or device alerts. Arrange monitoring during the first session, such as a clinic-supervised trial with ECG or device interrogation afterward. Do not use TENS unsupervised at home until the clinic has confirmed the device's recorded tracings are clean after a trial. Treat any shock from an ICD as an emergency and seek immediate evaluation.
Red flags that mean stop and call the clinic: palpitations, lightheadedness, syncope, a shock from an ICD, or any device alert or vibration. These are not "wait and see" symptoms in a patient with an implanted cardiac device.
Alternatives when TENS is off the table
| Option | Mechanism | Cardiac device concern | Notes |
|---|---|---|---|
| TENS | Surface electrical stimulation | Direct interference risk | Avoid near device; clinic clearance required |
| Heat therapy | Thermal vasodilation and muscle relaxation | None electrical | Superficial heat only; avoid over device pocket |
| Ice or cold packs | Reduced blood flow, numbed nerve endings | None electrical | Short applications; skin protection |
| Topical analgesics | Local drug absorption | None electrical | Follow label; check for interactions |
| Manual therapy or massage | Mechanical soft-tissue work | None electrical | Avoid pressure over generator pocket |
| Exercise or physical therapy | Load and conditioning | None electrical | Supervised program is often first-line |
| Acupuncture | Mechanical or electrical needling (electroacupuncture carries its own current) | Electrical variants carry risk | Confirm modality before proceeding |
Plain language: most non-electrical pain options do not interfere with a pacemaker, while anything that pushes current through the body needs the device team's sign-off.
The timeline for a supervised decision is short. Device interrogation after a trial typically happens within days to a couple of weeks, and the clinic can review stored electrograms for noise or sensed events. A trial without follow-up interrogation is incomplete, because the device records what the patient cannot feel.
Limitations of the evidence
The published data on TENS and implanted cardiac devices consists largely of bench testing, case reports, and small series, not large prospective trials. Bench studies isolate variables but do not fully reproduce human tissue conductivity and lead geometry. Case reports capture harms but cannot establish how often interference occurs without symptoms.
Device technology also outpaces the literature. Filters and sensing algorithms change between generations, so a finding from an older device may not transfer to a current one. That is a reason for device-specific guidance from the clinic rather than population-level rules.
Thresholds in labeling and guidance are not fully harmonized. TENS manufacturers state a blanket contraindication for implanted electronic devices, while some clinical guidance allows for individualized assessment. The reconciliation is straightforward: the labeling sets the default, and the device clinic can override it only for a specific patient after evaluating the specific device, and even then the safe zone is narrow. When the two sources conflict, the more restrictive one governs until the managing team documents otherwise.
One professional caveat deserves emphasis: the absence of a reported adverse event in a patient's history should not be read as clearance. Interference may be silent, and the appropriate standard is prospective device interrogation, not retrospective reassurance.